Hello, I am Meletios Dimopoulos.
I work at the National Kapodistrian University of Athens in Athens, Greece, at Alexandra Hospital, and I'm here participating at EHA 2025.
I would like to share the recent data regarding belantamab, pomalidomide, dexamethasone and combination, in the DREAMM-8 study.
In this particular trial, this combination with belantamab was compared to a standard of care with pomalidomide bortezomib and dexamethasone.
And recently we had an updated analysis which showed that the median progression free survival for the combination of belantamab, pomalidomide, and dexamethasone was 32 months, meaning that, it took a median of three years for patients with myeloma who received this combination to progress and to require another treatment.
This data are outstanding.
If one takes into consideration that belantamab can be given on an outpatient basis.
It is off the shelf.
And also, it can be given, every 2 or 3 months, depending on the tolerability of the drug.
We know that belantamab is associated with some ocular complications.
However, these are manageable.
They affect the cornea, meaning the anterior part of the eye.
And, they always regress when we hold the drug and when we restart at lower doses and at longer intervals.
That's the take home message from DREAMM-8 is that we have, an exceptionally long, median progression free survival and a real, interesting and active combination for patients with myeloma who have progressed on lenalidomide and also on one anti-CD38 monoclonal antibody, such as daratumumab or isatuximab.
And we know that these compounds are being given now more and more often in the frontline setting.
So they will be an enlarging patient population who will benefit from this belantamab based combination.
HealthTree • June 20, 2025